Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.33 |
| ▸ | LSS | P48449 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5274804 | 0.93 | ALDH1A1 (0.41) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL9651294 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL22813038 | 0.85 | ALDH1A1 (0.56) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL530011 | 0.84 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL5279475 | 0.83 | CA12 (0.41) | ALDH1A1TSHRKDM4EDNM1 | |
| SCHEMBL7763390 | 0.82 | ALDH1A1 (0.59) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL10566857 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL623374 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TSHRKDM4ESMN1; SMN2HRH3 | |
| SCHEMBL4602900 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRKDM4ESMN1; SMN2DNM1 | |
| SCHEMBL811337 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRKDM4ESMN1; SMN2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114611-A1 | Functionalized alkyllithium formulations with improved thermal stability and processes for making the same | FMC CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030114592-A1 | Processes for improving stability of living polymer chain ends | FMC CORPORATION | 2003-06-19 | — | — | US | claimed |
| US-20030032746-A1 | Hetero-telechelic polymers and processes for making same | FMC CORPORATION | 2003-02-13 | — | — | US | claimed |
| US-20030032745-A1 | Hetero-telechelic polymers and processes for making same | SCHWINDEMAN JAMES A (US) | 2003-02-13 | — | — | US | claimed |
| US-20030013827-A1 | Hetero-telechelic polymers and processes for making same | FMC CORPORATION | 2003-01-16 | — | — | US | claimed |
| EP-0842199-B1 | HETERO-TELECHELIC POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORP (US) | 2002-04-03 | — | — | EP | claimed |
| US-6221991-B1 | STAR POLYMER | FMC CORPORATION | 2001-04-24 | — | — | US | claimed |
| WO-2000050478-A1 | NOVEL FORMULATIONS OF ALKYLLITHIUMS WITH IMPROVED THERMAL STABILITY, PROCESSES TO PRODUCE THESE FORMULATIONS AND PROCESSES FOR USING THE SAME TO IMPROVE STABILITY OF LIVING POLYMER CHAIN ENDS | FMC CORPORATION (US) | 2000-08-31 | — | — | WO | claimed |
| EP-0842199-A1 | HETERO-TELECHELIC POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997006192-A1 | FUNCTIONALIZED POLYSTYRENE/POLYDIENE COPOLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-20 | — | — | WO | claimed |
| WO-1997006188-A1 | TELECHELIC POLYSTYRENE/POLYETHYLENE COPOLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-20 | — | — | WO | claimed |
| WO-1997005174-A1 | HETERO-TELECHELIC POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-13 | — | — | WO | claimed |
| WO-1997005173-A1 | METHACRYLATE AND ACRYLATE POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-13 | — | — | WO | claimed |
| EP-0827423-B1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORP (US) | 2007-12-12 | — | — | EP | disclosed |
| US-6703446-B2 | POLYMERS HAVING DIFFERENT FUNCTIONALITIES AT OPPOSITE ENDS OF THE POLYMER CHAIN; CAN BE COPOLYMERIZED WITH OTHER MONOMERS TO PROVIDE NOVEL COPOLYMERS POSSESSING A WIDE RANGE OF PHYSICAL PROPERTIES | FMC CORPORATION, LITHIUM DIVISION | 2004-03-09 | — | — | US | disclosed |
| US-6699939-B2 | POLYMERS HAVING DIFFERENT FUNCTIONALITIES AT OPPOSITE ENDS OF THE POLYMER CHAIN; CAN BE COPOLYMERIZED WITH OTHER MONOMERS TO PROVIDE NOVEL COPOLYMERS POSSESSING A WIDE RANGE OF PHYSICAL PROPERTIES | FMC CORPORATION, LITHIUM DIVISION | 2004-03-02 | — | — | US | disclosed |
| WO-1997005174-A1 | HETERO-TELECHELIC POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997005176-A1 | DEPROTECTION OF PROTECTED FUNCTIONAL POLYMERS | FMC CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1997005173-A1 | METHACRYLATE AND ACRYLATE POLYMERS AND PROCESSES FOR MAKING SAME | FMC CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| WO-1996035509-A1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORPORATION (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114611-A1 | Functionalized alkyllithium formulations with improved thermal stability and processes for making the same | AAAS, AS3MT, APC | ALDH1A1 1472/4885TSHR 2597/4885KDM4E 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.